Movement Alert｜BEIGENE Rises 4.13% in Regular Trading, Adds $300 Million Investment to Expand US Manufacturing

Market Focus07-24

On July 24, BEIGENE rose 4.13% in regular trading, trading at 201.0 HKD/share, with turnover of approximately HKD 165 million. The stock was lifted by multiple positive catalysts announced in recent days.

On the news front, the company announced on July 23 an additional $300 million investment to expand its US production footprint, further strengthening global commercialization capacity. Simultaneously, Amgen and BEIGENE jointly registered DeLLphi-315, the first Phase 3 clinical trial evaluating a subcutaneous formulation of Tarlatamab for recurrent extensive-stage small cell lung cancer, marking a significant pipeline advancement.

Additionally, the company's core product Brukinsa recently achieved the primary endpoint in the MANGROVE Phase 3 trial for first-line mantle cell lymphoma treatment, demonstrating a 43% reduction in disease progression or death risk versus standard immunochemotherapy. The company plans to pursue global regulatory submissions in the second half of the year. BEIGENE is scheduled to hold its Q2 earnings call on August 5.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190666268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190666268","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEIGENE Rises 4.13% in Regular Trading, Adds $300 Million Investment to Expand US Manufacturing","media":"Market Focus","content":"<p><p>On July 24, BEIGENE rose 4.13% in regular trading, trading at 201.0 HKD/share, with turnover of approximately HKD 165 million. The stock was lifted by multiple positive catalysts announced in recent days.</p><p>On the news front, the company announced on July 23 an additional $300 million investment to expand its US production footprint, further strengthening global commercialization capacity. Simultaneously, Amgen and BEIGENE jointly registered DeLLphi-315, the first Phase 3 clinical trial evaluating a subcutaneous formulation of Tarlatamab for recurrent extensive-stage small cell lung cancer, marking a significant pipeline advancement.</p><p>Additionally, the company's core product Brukinsa recently achieved the primary endpoint in the MANGROVE Phase 3 trial for first-line mantle cell lymphoma treatment, demonstrating a 43% reduction in disease progression or death risk versus standard immunochemotherapy. The company plans to pursue global regulatory submissions in the second half of the year. BEIGENE is scheduled to hold its Q2 earnings call on August 5.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEIGENE Rises 4.13% in Regular Trading, Adds $300 Million Investment to Expand US Manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEIGENE Rises 4.13% in Regular Trading, Adds $300 Million Investment to Expand US Manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, BEIGENE rose 4.13% in regular trading, trading at 201.0 HKD/share, with turnover of approximately HKD 165 million. The stock was lifted by multiple positive catalysts announced in recent days.</p><p>On the news front, the company announced on July 23 an additional $300 million investment to expand its US production footprint, further strengthening global commercialization capacity. Simultaneously, Amgen and BEIGENE jointly registered DeLLphi-315, the first Phase 3 clinical trial evaluating a subcutaneous formulation of Tarlatamab for recurrent extensive-stage small cell lung cancer, marking a significant pipeline advancement.</p><p>Additionally, the company's core product Brukinsa recently achieved the primary endpoint in the MANGROVE Phase 3 trial for first-line mantle cell lymphoma treatment, demonstrating a 43% reduction in disease progression or death risk versus standard immunochemotherapy. The company plans to pursue global regulatory submissions in the second half of the year. BEIGENE is scheduled to hold its Q2 earnings call on August 5.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1190666268","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190666268","pubTimestamp":1784857772,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, BEIGENE rose 4.13% in regular trading, trading at 201.0 HKD/share, with turnover of approximately HKD 165 million. The stock was lifted by multiple positive catalysts announced in recent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势提醒|百济神州常规交易上涨4.13%，追加3亿美元投资扩大美国制造业","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On July 24, BEIGENE rose 4.13% in regular trading, trading at 201.0 HKD/share, with turnover of approximately HKD 165 million. The stock was lifted by multiple positive catalysts announced in recent days.On the news front, the company announced on July 23 an additional $300 million investment to expand its US production footprint, further strengthening global commercialization capacity. Simultaneously, Amgen and BEIGENE jointly registered DeLLphi-315, the first Phase 3 clinical trial evaluating a subcutaneous formulation of Tarlatamab for recurrent extensive-stage small cell lung cancer, marking a significant pipeline advancement.Additionally, the company's core product Brukinsa recently achieved the primary endpoint in the MANGROVE Phase 3 trial for first-line mantle cell lymphoma treatment, demonstrating a 43% reduction in disease progression or death risk versus standard immunochemotherapy. The company plans to pursue global regulatory submissions in the second half of the year. BEIGENE is scheduled to hold its Q2 earnings call on August 5.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190666268","isCrawlerRequest":true}